系统性红斑狼疮生物制剂治疗研究进展

Advances in biological treatment for systemic lupus erythematosus

系统性红斑狼疮（SLE）是常见的自身免疫性疾病，其发病机制复杂，临床表现多样。目前常规治疗手段虽能改善SLE的临床症状和降低病死率，但仍有部分难治性病例对常规治疗无应答。随着SLE发病机制在分子生物学和细胞免疫学方面的研究进展，靶向SLE免疫学异常不同环节的特异性生物治疗也在不断发展。本研究聚焦目前研究和应用新型治疗SLE的生物制剂，包括影响B淋巴细胞活化、T淋巴细胞与B淋巴细胞相互作用、细胞因子相关及免疫耐受相关生物制剂。

Systemic lupus erythematosus （SLE） is a common autoimmune disease with complex pathogenesis and significant clinical heterogeneity. The conventional therapies for SLE are effective in reducing clinical symptom and mortality, but some refractory patients are still nonreactive to current treatments. Recent advances in understanding of the molecular and cellular immunology of SLE pathogenesis have led to the development of novel biological treatments targeting on the different dysregulated immunological pathways involved in SLE pathogenesis. This review presents the current and the near-future novel biological immune targeted treatments, such as B cell-targeted therapy, T ce11-B cell interaction blockade, cytokine blockade and immune tolerance agent.